$RXDX News

Last published 2y ago

2y agoRXDXCellino Appoints Chris Gibson to Board of DirectorsBusiness WireCellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of
3y agoMRK RXDXMerck Completes Acquisition of Prometheus Biosciences, Inc.Business WireAcquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside
3y agoRXDXPrometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressGlobeNewswireSAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and
3y agoHUGE MRK OMER RXDXNorth America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks IndustryPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., April 18, 2023 /PRNewswire/ -- Alcohol consumption and drug abuse have become public health concerns worldwide. Governments are working on ways to detect any
3y agoRXDX MTB STT SEDG+9Stocks making the biggest moves midday: Alphabet, Charles Schwab, State Street, Moderna and moreCNBCThese are the stocks posting the largest moves in midday trading.
3y agoRXDX MRK SCHW GOOG+15Stocks making the biggest moves premarket: Charles Schwab, Dell, Alphabet, HP Inc. & moreCNBCJPMorgan downgraded Dell to neutral from overweight, citing its preference for HP's expected recovery in the PC segment.
3y agoRXDXPrometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and
3y agoRXDXPrometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – – Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 – – Initiated a third
3y agoRXDXPrometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)GlobeNewswire- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3rd - - Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from Cohort 1 to be presented
3y agoRXDXPrometheus Biosciences to Present at the SVB Securities Global Biopharma ConferenceGlobeNewswireSAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and
3y agoRXDXPrometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and
3y agoRXDXPrometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common StockGlobeNewswireSAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and
3y agoBMY GILD ONCY RNAZ+1Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028PR NewswirePALM BEACH, Fla., Dec. 8, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which exceeded USD 25.5 billion in
3y agoRXDXPrometheus Biosciences, Inc. Announces Proposed Public Offering of Common StockGlobeNewswireSAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and
3y agoRXDXPrometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAbGlobeNewswire– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary
4y agoRXDXPrometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position provides runway into
4y agoRXDXPrometheus Biosciences to Participate at November Healthcare ConferencesGlobeNewswireSAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and
4y agoRXDXPrometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052GlobeNewswire- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF - - PRA052 is the second clinical candidate identified using the Prometheus360™
4y agoRXDXPrometheus Biosciences to Participate at September Healthcare ConferencesGlobeNewswireSAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and comp
4y agoRXDXPrometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging study - - Unveiled Prometheus' second precision ca
4y agoRXDXPrometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022GlobeNewswire- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 - - PRA052 is a novel, first-in-class monoclonal antibody ad
4y agoRXDXPrometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 StudiesGlobeNewswire- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn's disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - - Both APOLLO-CD and ARTEMIS-UC topline results expec
4y agoRXDXPrometheus Biosciences to Participate at the Jefferies Healthcare ConferenceGlobeNewswireSAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and compa
4y agoRXDXPrometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - - Announced key appointments in Leadership Team -
4y agoRXDXPrometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)GlobeNewswire- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has granted Fast Track Designation for PRA023 for the treat
4y agoRXDXPrometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn's disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) on track to initiat
4y agoRXDXPrometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and com
4y agoRXDXPrometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and comp
4y agoRXDXPrometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheu
4y agoRXDXPrometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and comp
4y agoRXDXPrometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone PaymentGlobeNewswireSAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and comp
4y agoRXDXPrometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)GlobeNewswirePhase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 i
5y agoRXDXPrometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - - Enrollment on track for Phase 2 in ulcerative colitis and Phase 2a in Crohn's disease wit
5y agoRXDXPrometheus Biosciences to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and comp
5y agoFLAC ISEE KRYS RCKT+4Frazier Healthcare Partners Announces Several Promotions on Life Sciences TeamBusiness WireFrazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabra
5y agoRXDXPrometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics SummitGlobeNewswireSAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Je
5y agoRXDXPrometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in
5y agoRXDXIn Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed AwayGlobeNewswireSAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed away unexpectedly on August 4, 2021. "As I reflect
5y agoRXDXPrometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn's DiseaseGlobeNewswire- First Anti-TL1A trial in Crohn's Disease - - APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal healthy volunteers expected in fourth quarter 2021- S
5y agoRXDXPrometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021GlobeNewswireSAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and comp
5y agoARQT PASG PHAT RXDX+1Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening LeadershipBusiness WireEleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertis
5y agoRXDXPrometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ PlatformGlobeNewswire-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- -IND for PR600 expected in 3Q 2022- SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotech
5y agoRXDXPrometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and compa
5y agoRXDXFred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences BoardGlobeNewswireSAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and compa
5y agoRXDXPrometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireSAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and compa
5y agoRXDXPrometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewswire-PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn's Disease in 3Q 2021- -Launched Prometheus Enroll360™, a global patient recruitment platform for accelerated patient enrollment in fut
5y agoRXDXPrometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesPR NewswirePrometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and...
5y agoRXDX021, 22:26 ET Prometheus Biosciences Announces Upsized Pricing of Initial Public OfferingPR NewswirePrometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and...
10y agoRXDXIgnyta's (RXDX) CEO Jonathan Lim on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts